Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase

Journal of Virology

Volumn 88, Issue 5, 2014, Pages 2584-2599

  Vörös, Judit ^a   Urbanek, Annika ^a   Rautureau, Gilles Jean Philippe ^a,c   O'Connor, Maggie ^a   Fisher, Henry C ^b   Ashcroft, Alison E ^b   Ferguson, Neil ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS POLYMERASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VIRUS ENZYME;

ALPHA HELIX; ARTICLE; BETA SHEET; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SYNTHESIS; ESCHERICHIA COLI; HEPATITIS B VIRUS; IN VITRO STUDY; METAL BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION;

ALGORITHMS; CIRCULAR DICHROISM; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HUMANS; MASS SPECTROMETRY; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; RIBONUCLEOPROTEINS;

EID: 84896739556     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02575-13     Document Type: Article

References (88)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212-2219. http://dx.doi.org/10 .1016/j.vaccine.2011.12.116.
2. Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim S-O, Folk WR, Sarafianos SG. 2012. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int. J. Biochem. Cell Biol. 44:1060-1071. http://dx.doi.org /10.1016/j.biocel.2012.04.006.
3. Zoulim F. 2011. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 31(Suppl 1):111-116. http://dx.doi.org/10.1111/j .1478-3231.2010.02399.x.
4. Bhattacharya D, Thio CL. 2010. Review of hepatitis B therapeutics. Clin. Infect. Dis. 51:1201-1208. http://dx.doi.org/10.1086/656624.
5. Matthews SJ. 2006. Entecavir for the treatment of chronic hepatitis B virus infection. Clin. Ther. 28:184-203. http://dx.doi.org/10.1016/j .clinthera.2006.02.012.
6. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J. Gastroenterol. 13:48-64. http://www.wjgnet.com/1007-9327/13/48.asp.
7. Nassal M. 1999. Hepatitis B virus replication: novel roles for virus-host interactions. Intervirology 42:100-116. http://dx.doi.org/10.1159 /000024970.
8. Nassal M. 2008. Hepatitis B viruses: reverse transcription a different way. Virus Res. 134:235-249. http://dx.doi.org/10.1016/j.virusres.2007.12.024.
9. Chen Y, Robinson WS, Marion PL. 1994. Selected mutations of the duck hepatitis B virus P gene RNase H domain affect both RNA packaging and priming of minus-strand DNA synthesis. J. Virol. 68:5232-5238.
10. Radziwill G, Tucker W, Schaller H. 1990. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J. Virol. 64:613-620.
11. Toh H, Hayashida H, Miyata T. 1983. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 305:827-829. http://dx.doi.org /10.1038/305827a0.
12. Xiong Y, Eickbush TH. 1990. Origin and evolution of retroelements based upon their reverse transcriptase sequences. EMBO J. 9:3353-3362.
13. Lanford RE, Notvall L, Lee H, Beames B. 1997. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. 71:2996-3004.
14. Weber M, Bronsema V, Bartos H, Bosserhoff A, Bartenschlager R, Schaller H. 1994. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J. Virol. 68:2994-2999.
15. Zoulim F, Seeger C. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.
16. Hu J, Flores D, Toft D, Wang X, Nguyen D. 2004. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J. Virol. 78:13122-13131. http://dx.doi.org/10.1128/JVI.78.23.13122 -13131.2004.
17. Jones SA, Boregowda R, Spratt TE, Hu J. 2012. In vitro epsilon RNAdependent protein priming activity of human hepatitis B virus polymerase. J. Virol. 86:5134-5150. http://dx.doi.org/10.1128/JVI.07137-11.
18. Lott L, Beames B, Notvall L, Lanford RE. 2000. Interaction between hepatitis B virus core protein and reverse transcriptase. J. Virol. 74:11479-11489. http://dx.doi.org/10.1128/JVI.74.24.11479-11489.2000.
19. Wang G-H, Seeger C. 1993. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:6507-6512.
20. Lewellyn EB, Loeb DD. 2011. The arginine clusters of the carboxyterminal domain of the core protein of hepatitis B virus make pleiotropic contributions to genome replication. J. Virol. 85:1298-1309. http://dx.doi .org/10.1128/JVI.01957-10.
21. Field HJ, Mickleburgh I. 2013. The helicase-primase complex as a target for effective herpesvirus antivirals. Adv. Exp. Med. Biol. 767:145-159. http://dx.doi.org/10.1007/978-1-4614-5037-5_7.
22. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47: 3123-3129. http://dx.doi.org/10.1128/AAC.47.10.3123-3129.2003.
23. Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, Wahling H, Wickstrom K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K. 2008. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitisCvirus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 18:4853-4858. http://dx.doi .org/10.1016/j.bmcl.2008.07.088.
24. Tsantrizos YS. 2004. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061, from the NMR tube to the clinic. Biopolymers 76:309-323. http://dx.doi.org/10.1002/bip.20127.
25. von Itzstein M, Wu W-Y, Kok GB, Pegg MS, Dyason JC, Jin B, Phan TV, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423. http://dx.doi.org/10.1038/363418a0.
26. Choi J, Kim EE, Park YI, Han YS. 2002. Expression of the active human and duck hepatitis B virus polymerases in heterologous system of Pichia methanolica. Antiviral Res. 55:279-290. http://dx.doi.org/10.1016/S0166 -3542(02)00023-2.
27. Kim SS, Shin HJ, Cho YH, Rho HM. 2000. Expression of stable hepatitis B viral polymerase associated with GRP94 in E. coli. Arch. Virol. 145: 1305-1320. http://dx.doi.org/10.1007/s007050070092.
28. Yu Y, Pandeya DR, Liu M-L, Liu M-J, Hong S-T. 2010. Expression and purification of a functional human hepatitis B virus polymerase. World J. Gastroenterol. 16:5752-5758. http://dx.doi.org/10.3748/wjg.v16.i45.5752.
29. Ayola B, Kanda P, Lanford RE. 1993. High level expression and phosphorylation of hepatitis B virus polymerase in insect cells with recombinant baculoviruses. Virology 194:370-373. http://dx.doi.org/10.1006 /viro.1993.1270.
30. Cho G, Na S, Suh SW, Jung G. 2000. Expression of recombinant HBV Pol proteins in HepG2 cells. J. Biochem. Mol. Biol. 33:440-447. http://www.jbmb.or.kr/view_article.php3?cont=jbmb&kid=7&mid=2&pid=2.
31. Urban M, McMillan DJ, Canning G, Newell A, Brown E, Mills JS, Jupp R. 1998. In vitro activity of hepatitis B virus polymerase: requirement for distinct metal ions and the viral epsilon stem-loop. J. Gen. Virol. 79:1121-1131.
32. Beck J, Nassal M. 1997. Sequence-and structure-specific determinants in the interaction between the RNA encapsidation signal and reverse transcriptase of avian hepatitis B viruses. J. Virol. 71:4971-4980.
33. Beck J, Nassal M. 1998. Formation of a functional hepatitis B virus replication initiation complex involves a major structural alteration in the RNA template. Mol. Cell. Biol. 18:6265-6272.
34. Lanford RE, Kim Y-H, Lee H, Notvall L, Beames B. 1999. Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction. J. Virol. 73:1885-1893.
35. Stahl M, Beck J, Nassal M. 2007. Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding. J. Virol. 81:13354-13364. http://dx.doi.org/10.1128/JVI.01196-07.
36. Beck J, Nassal M. 2001. Reconstitution of a functional duck hepatitis B virus replication initiation complex from separate reverse transcriptase domains expressed in Escherichia coli. J. Virol. 75:7410-7419. http://dx .doi.org/10.1128/JVI.75.16.7410-7419.2001.
37. Hu J, Anselmo D. 2000. In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90. J. Virol. 74:11447-11455. http://dx.doi.org/10.1128/JVI.74.24 .11447-11455.2000.
38. Hu J, Seeger C. 1996. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 93:1060-1064.
39. Beck J, Nassal M. 2003. Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein. J. Biol. Chem. 278:36128-36138. http://dx .doi.org/10.1074/jbc.M301069200.
40. Hu J, Toft D, Anselmo D, Wang X. 2002. In vitro reconstitution of functional hepadnavirus reverse transcriptase with cellular chaperone proteins. J. Virol. 76:269-279. http://dx.doi.org/10.1128/JVI.76.1.269 -279.2002.
41. Stahl M, Retzlaff M, Nassal M, Beck J. 2007. Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system. Nucleic Acids Res. 35:6124-6136. http://dx.doi.org/10.1093/nar/gkm628.
42. Beck J, Nassal M. 2011. A Tyr residue in the reverse transcriptase domain can mimic the protein-priming Tyr residue in the terminal protein domain of a hepadnavirus P protein. J. Virol. 85:7742-7753. http://dx.doi .org/10.1128/JVI.00482-11.
43. Boregowda RK, Lin L, Zhu Q, Tian F, Hu J. 2011. Cryptic protein priming sites in two different domains of duck hepatitis B virus reverse transcriptase for initiating DNA synthesis in vitro. J. Virol. 85:7754-7765. http://dx.doi.org/10.1128/JVI.00483-11.
44. Wang X, Qian X, Guo H-C, Hu J. 2003. Heat shock protein 90-independent activation of truncated hepadnavirus reverse transcriptase. J. Virol. 77:4471-4480. http://dx.doi.org/10.1128/JVI.77.8.4471-4480.2003.
45. Hu J, Boyer M. 2006. Hepatitis B virus reverse transcriptase and epsilon RNAsequences required for specific interaction in vitro. J. Virol. 80:2141-2150. http://dx.doi.org/10.1128/JVI.80.5.2141-2150.2006.
46. Jones SA, Hu J. 2013. Protein-primed terminal transferase activity of hepatitis B virus polymerase. J. Virol. 87:2563-2576. http://dx.doi.org/10 .1128/JVI.02786-12.
47. Ghosh AK, Dawson ZL, Mitsuya H. 2007. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg. Med. Chem. 15:7576-7580. http://dx.doi.org/10.1016.j.bmc.2007.09.010.
48. Yin PD, Das D, Mitsuya H. 2006. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Cell. Mol. Life Sci. 63:1706-1724. http: //dx.doi.org/10.1007/s00018-006-6009-7.
49. Kleymann G. 2005. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin. Invest. Drugs 14:135-161. http://dx.doi.org/10.1517/13543784.14.2.135.
50. Lin L, Wan F, Hu J. 2008. Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions. J. Virol. 82:5703-5714. http://dx.doi .org/10.1128/JVI.02760-07.
51. Tavis JE, Ganem D. 1996. Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template. J. Virol. 70:5741-5750.
52. Tavis JE, Massey B, Gong Y. 1998. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. J. Virol. 72:5789-5796.
53. Ménoret A. 2004. Purification of recombinant and endogenous HSP70s. Methods 32:7-12. http://dx.doi.org/10.1016/S1046-2023(03)00180-4.
54. Buchner J, Weikl T, Bugl H, Pirkl F, Bose S. 1998. Purification of Hsp90 partner proteins Hop/p60, p23, and FKBP52. Methods Enzymol. 290: 418-429.
55. McLaughlin SH, Smith HW, Jackson SE. 2002. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J. Mol. Biol. 315:787-798. http://dx.doi.org/10.1006.jmbi.2001.5245.
56. Jürgens MC, Vörös J, Rautureau GJP, Shepherd Da, Pye VE, Muldoon J, Johnson CM, Ashcroft AE, Freund SMV, Ferguson N. 2013. The hepatitis B virus preS1 domain hijacks host trafficking proteins by motif mimicry. Nat. Chem. Biol. 9:540-547. http://dx.doi.org/10.1038/nchem bio.1294.
57. Combet C, Blanchet C, Geourjon C, Deléage G. 2000. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25:147-150. http://dx.doi .org/10.1016/S0968-0004(99)01540-6.
58. Eudes R, Le Tuan K, Delettré J, Mornon J-P, Callebaut I. 2007. A generalized analysis of hydrophobic and loop clusters within globular protein sequences. BMC Struct. Biol. 7:2. http://dx.doi.org/10.1186/1472 -6807-7-2.
59. Campo DS, Dimitrova Z, Lara J, Purdy M, Thai H, Ramachandran S, Ganova-Raeva L, Zhai X, Forbi JC, Teo CG, Khudyakov Y. 2011-2012. Coordinated evolution of the hepatitis B virus polymerase. In Silico Biol. 11:175-182. http://dx.doi.org/10.3233/ISB-2012-0452.
60. Bartenschlager R, Schaller H. 1988. The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J. 7:4185-4192.
61. Boregowda RK, Adams C, Hu J. 2012. TP-RT domain interactions of duck hepatitis B virus reverse transcriptase in cis and in trans during protein-primed initiation of DNA synthesis in vitro. J. Virol. 86:6522-6536. http://dx.doi.org/10.1128/JVI.00086-12.
62. Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG. 2013. The hepatitis B virus ribonucleaseHis sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 9(1): e1003125. http://dx.doi.org/10.1371/journal.ppat.1003125.
63. de Marco A, Deuerling E, Mogk A, Tomoyasu T, Bukau B. 2007. Chaperone-based procedure to increase yields of soluble recombinant proteins produced in E. coli. BMC Biotechnol. 7:32. http://dx.doi.org/10 .1186/1472-6750-7-32.
64. Popot J-L, Althoff T, Bagnard D, Banères J-L, Bazzacco P, Billon-Denis E, Catoire LJ, Champeil P, Charvolin D, Cocco MJ, Crémel G, Dahmane T, de la Maza LM, Ebel C, Gabel F, Giusti F, Gohon Y, Goormaghtigh E, Guittet E, Kleinschmidt JH, Kühlbrandt W, Le Bon C, Martinez KL, Picard M, Pucci B, Sachs JN, Tribet C, van Heijenoort C, Wien F, Zito F, Zoonens M. 2011. Amphipols from A to Z. Annu. Rev. Biophys. 40:379-408. http://dx.doi.org/10.1146/annurev-biophys-0429 10-155219.
65. Wei X, Peterson DL. 1996. Expression, purification, and characterization of an active RNase H domain of the hepatitis B viral polymerase. J. Biol. Chem. 271:32617-32622.
66. Sreerama N, Woody RW. 2000. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal. Biochem. 287:252-260. http://dx.doi.org/10.1006/abio.2000.4880.
67. Alexander CG, Jürgens MC, Shepherd DA, Freund SM, Ashcroft AE, Ferguson N. 2013. Thermodynamic origins of protein folding, allostery, and capsid formation in the human hepatitis B virus core protein. Proc. Natl. Acad. Sci. U. S. A. 110:E2782-E2791. http://dx.doi.org/10.1073/pnas .1308846110.
68. Roesler KR, Rao AG. 1999. Conformation and stability of barley chymotryp-sin inhibitor-2 (CI-2) mutants containing multiple lysine substitutions. Protein Eng. 12:967-973. http://dx.doi.org/10.1093/protein/12.11.967.
69. Stevens JC, Chia R, Hendriks WT, Bros-Facer V, van Minnen J, Martin JE, Jackson GS, Greensmith L, Schiavo G, Fisher EM. 2010. Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag: implications for research into amyotrophic lateral sclerosis (ALS). PLoS One 5(3): e9541. http://dx.doi.org/10.1371/journal.pone.0009541.
70. Slotboom DJ, Duurkens RH, Olieman K, Erkens GB. 2008. Static light scattering to characterize membrane proteins in detergent solution. Methods 46:73-82. http://dx.doi.org/10.1016/j.ymeth.2008.06.012.
71. Theisen A. 2000. Refractive increment data book for polymer and biomolecular scientists. Nottingham University Press, Nottingham, United Kingdom.
72. Ruotolo BT, Robinson CV. 2006. Aspects of native proteins are retained in vacuum. Curr. Opin. Chem. Biol. 10:402-408. http://dx.doi.org/10.10 16/j.cbpa.2006.08.020.
73. Smith DP, Giles K, Bateman RH, Radford SE, Ashcroft AE. 2007. Monitoring copopulated conformational states during protein folding events using electrospray ionization-ion mobility spectrometry-mass spectrometry. J. Am. Soc. Mass Spectrom. 18:2180-2190. http://dx.doi .org/10.1016/j.jasms.2007.09.017.
74. Smith DP, Knapman TW, Campuzano I, Malham RW, Berryman JT, Radford SE, Ashcroft AE. 2009. Deciphering drift time measurements from travelling wave ion mobility spectrometry-mass spectrometry studies. Eur. J. Mass Spectrom. (Chichester, Eng.) 15:113-130. http://dx.doi .org/10.1255/ejms.947.
75. Gohon Y, Giusti F, Prata C, Charvolin D, Timmins P, Ebel C, Tribet C, Popot JL. 2006. Well-defined nanoparticles formed by hydrophobic assembly of a short and polydisperse random terpolymer, amphipol A8-35. Langmuir 22:1281-1290. http://dx.doi.org/10.1021/la052243g.
76. Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S. 2011. Molecular interaction studies using microscale thermophoresis. Assay Drug Dev. Technol. 9:342-353. http://dx.doi.org/10.01089/adt.2011.0380.
77. Pierce MM, Raman CS, Nall BT. 1999. Isothermal titration calorimetry of protein-protein interactions. Methods 19:213-221. http://dx.doi.org /10.1006/meth.1999.0852.
78. Badtke MP, Khan I, Cao F, Hu J, Tavis JE. 2009. An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription. Virology 390:130-138. http://dx.doi.org/10.1016/j.virol .2009.04.023.
79. Wang Y-X, Wen Y-M, Nassal M. 2012. Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids. J. Virol. 86:10079 -10092. http://dx.doi.org/10.1128/JVI.00816-12.
80. Potenza N, Salvatore V, Raimondo D, Falanga D, Nobile V, Peterson DL, Russo A. 2007. Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active. Protein Expr. Purif. 55:93-99. http://dx.doi.org/10 .1016/j.pep.2007.04.005.
81. Fan C-Y, Lee S, Cyr DM. 2003. Mechanisms for regulation of Hsp70 function by Hsp40. Cell Stress Chaperones 8:309-316. http://dx.doi.org /10.1379/1466-1268(2003)0080309:MFROHF2.0.CO;2.
82. Mayer MP, Bukau B. 2005. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci. 62:670-684. http://dx.doi.org /10.1007/s00018-004-4464-6.
83. Pearl LH, Prodromou C. 2006. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75:271-294. http: //dx.doi.org/10.1146/annurev.biochem.75.103004.142738.
84. Kay A, Zoulim F. 2007. Hepatitis B virus genetic variability and evolution. Virus Res. 127:164-176. http://dx.doi.org/10.1016/j.virusres.2007.02.021.
85. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757. http://dx.doi.org/10.1053/jhep.2001.22166.
86. Hu J, Toft DO, Seeger C. 1997. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids.EMBOJ. 16:59-68. http://dx.doi.org/10 .1093/emboj/16.1.59.
87. Lanford RE, Notvall L, Beames B. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
88. Merelo JJ, Andrade MA, Prieto A, Moran F. 1994. Proteinotopic feature maps. Neurocomputing 6:443-454. http://dx.doi.org/10.1016/0925-2312 (94)90021-3.